Biomarin公司以高达2000万的金额获得Ibex公司的
NEW YORK (Reuters Health) - BioMarin Pharmaceutical Inc. has definitively agreed to buy Canadian firm IBEX Technologies' entire therapeutics pipeline, including phase II lead coagulant Neutralase (heparinase), it said on Wednesday.
The deal has an upfront value of $10.5 million, which BioMarin will pay in shares of common stock, excepting $2 million paid in cash. IBEX could receive up to $9.5 million more upon US regulatory approvals of agents acquired by BioMarin.
, 百拇医药
IBEX's portfolio of enzyme therapeutics complements BioMarin's existing product pipeline for serious, life-threatening conditions, the Novato, California-based firm said.
IBEX's Neutralase reverses the anti-clotting effect of heparin, and other new heparin alternatives, BioMarin believes. Injectable enzyme Neutralase cleaves heparin in a manner similar to that of BioMarin's enzyme-replacement therapies Aldurazyme and rhASB, which are being developed to treat fatal glycolipid disorders MPS I and MPS VI.
, 百拇医药
The agent has potential initial uses in coronary artery bypass graft (CABG) procedures and angioplasties, BioMarin said. It estimates that some "300,000 CABG surgeries and 725,000 angioplasties each year in the US could potentially benefit from heparin reversal," with approximately matching figures for Europe.
Due to promising data for Neutralase, IBEX intends to launch a phase III trial of the agent for use in coronary artery bypass graft surgery in 2002, it said.
, 百拇医药
BioMarin investor relations spokesman Jeremy T. Price told Reuters Health on Wednesday that "we aren't at a point yet where we have our estimate as far as exactly when it will hit the market or how much we'll be charging for it."
However, US Bancorp Piper Jaffray is already predicting "Neutralase will rapidly penetrate a $250 million [global] market upon its launch in 2005," the brokerage's Peter L. Ginsberg told Reuters Health on Wednesday.
, 百拇医药
Another agent acquired in the deal is the early-stage agent Phenylase, a potential enzyme therapy for Phenylketonuria (PKU). A genetic disease caused by an enzyme deficiency, PKU can lead to severe and irreversible mental retardation.
There are currently no drugs on the market to treat the condition, and the only available therapy is diet management. Most phenylketonurics control their condition by avoiding phenylalanine-rich foods, especially proteins; their dietary needs for protein are met by a prescribed protein supplement, according to IBEX.
, http://www.100md.com
Annual cost of special foods and supplements for the condition is over $5,000 per patient, BioMarin said. With some 50,000 patients in the US and Europe affected by the illness, there is a potential market of $250 million for Phenylase, BioMarin's Price said in a phone interview on Wednesday. However, the agent is not expected to enter the clinic until 2003, he noted.
On the NASDAQ, BioMarin shares jumped 1.40, almost 15%, to close at 10.80 on Wednesday. On the Toronto Stock Exchange, IBEX shares closed up 0.33 at 0.59., 百拇医药
The deal has an upfront value of $10.5 million, which BioMarin will pay in shares of common stock, excepting $2 million paid in cash. IBEX could receive up to $9.5 million more upon US regulatory approvals of agents acquired by BioMarin.
, 百拇医药
IBEX's portfolio of enzyme therapeutics complements BioMarin's existing product pipeline for serious, life-threatening conditions, the Novato, California-based firm said.
IBEX's Neutralase reverses the anti-clotting effect of heparin, and other new heparin alternatives, BioMarin believes. Injectable enzyme Neutralase cleaves heparin in a manner similar to that of BioMarin's enzyme-replacement therapies Aldurazyme and rhASB, which are being developed to treat fatal glycolipid disorders MPS I and MPS VI.
, 百拇医药
The agent has potential initial uses in coronary artery bypass graft (CABG) procedures and angioplasties, BioMarin said. It estimates that some "300,000 CABG surgeries and 725,000 angioplasties each year in the US could potentially benefit from heparin reversal," with approximately matching figures for Europe.
Due to promising data for Neutralase, IBEX intends to launch a phase III trial of the agent for use in coronary artery bypass graft surgery in 2002, it said.
, 百拇医药
BioMarin investor relations spokesman Jeremy T. Price told Reuters Health on Wednesday that "we aren't at a point yet where we have our estimate as far as exactly when it will hit the market or how much we'll be charging for it."
However, US Bancorp Piper Jaffray is already predicting "Neutralase will rapidly penetrate a $250 million [global] market upon its launch in 2005," the brokerage's Peter L. Ginsberg told Reuters Health on Wednesday.
, 百拇医药
Another agent acquired in the deal is the early-stage agent Phenylase, a potential enzyme therapy for Phenylketonuria (PKU). A genetic disease caused by an enzyme deficiency, PKU can lead to severe and irreversible mental retardation.
There are currently no drugs on the market to treat the condition, and the only available therapy is diet management. Most phenylketonurics control their condition by avoiding phenylalanine-rich foods, especially proteins; their dietary needs for protein are met by a prescribed protein supplement, according to IBEX.
, http://www.100md.com
Annual cost of special foods and supplements for the condition is over $5,000 per patient, BioMarin said. With some 50,000 patients in the US and Europe affected by the illness, there is a potential market of $250 million for Phenylase, BioMarin's Price said in a phone interview on Wednesday. However, the agent is not expected to enter the clinic until 2003, he noted.
On the NASDAQ, BioMarin shares jumped 1.40, almost 15%, to close at 10.80 on Wednesday. On the Toronto Stock Exchange, IBEX shares closed up 0.33 at 0.59., 百拇医药